Predictors of Mortality in Nondemented Patients With Parkinson Disease: Motor Symptoms Versus Nonmotor Symptoms

Abstract

Background and Objective:

The aim of this study is to identify risk factors for mortality in a community-based cohort of nondemented patients with Parkinson disease (PD) during prospective long-term follow-up, while also comparing the effect of motor complications to nonmotor symptoms (NMS) on risk of mortality.

Methods:

One hundred forty seven nondemented patients with PD (57.1% males; 70.9 ± 8.6 years old) were included in this 48 month follow-up, longitudinal, single, evaluation study. Motor and therapy-related complications were assessed using the Unified Parkinson’s Disease Rating Scale/part-IV (UPDRS-IV). Non-Motor Symptoms Scale (NMSS) total score was used to assess NMS burden. Cox proportional hazard models were applied to identify independent predictors of mortality during follow-up.

Results:

Twenty-two patients of 146 (15.1%) died (1 case without information). Both UPDRS-IV and NMSS total scores were higher at baseline in patients with PD who died (3.5 ± 3.1 vs 2.4 ± 2.4, P = .049 and 96.9 ± 58.6 vs 61.9 ± 51.0, P = .004, respectively). Unadjusted hazard ratios (HRs) associated with UPDRS-IV and NMSS total scores among those who died during follow-up were 1.171 (95% confidence interval [CI]: 1.012-1.357; P = .035) and 1.008 (95% CI: 1.002-1.013; P = .006), respectively. Independent predictors of mortality during follow-up after adjusting for other covariates were UPDRS-IV (HR: 1.224; 95% CI: 1.002-1.494; P = .047), age (HR: 1.231; 95% CI: 1104-1.374; P < .0001), and comorbidity (Charlson Index; HR: 1.429; 95% CI: 1.023-1.994; P = .036), but not NMSS total score (HR: 1.005; 95% CI: 0.996-1.014; P = .263).

Conclusions:

Both motor complications (UPDRS-IV) and NMS (NMSS) were associated with mortality at 4 years, being motor complications an independent predictor of it.

Keywords

comorbidity motor complications mortality nonmotor symptoms outcome Parkinson disease

Get full access to this article

View all access options for this article.

References

Jankovic

. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368–376.

Schrag

Horsfall

Walters

Noyce

Petersen

. Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol. 2015;14(1):57–64.

Lee

Koh

. Many faces of Parkinson’s disease: non-motor symptoms of Parkinson’s disease. J Mov Disord. 2015;8(2):92–97.

Seppi

Weintraub

Coelho

. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(suppl 3):S42–S80.

Martinez-Martin

Rodriguez-Blazquez

Kurtis

Chaudhuri

; NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord. 2011;26(3):399–406.

Hinnell

Hurt

Landau

Brown

Samuel

; PROMS-PD Study Group. Nonmotor versus motor symptoms: how much do they matter to health status in Parkinson’s disease? Mov Disord. 2012;27(2):236–241.

Schrag

Choudhury

Kaski

Gallagher

. Why do patients with Parkinson’s disease fall? A cross-sectional analysis of possible causes of falls. NPJ Parkinsons Dis. 2015;1:15011.

Gong

Man

Fan

. Parkinson's disease and risk of mortality: meta-analysis and systematic review. Acta Neurol Scand. 2014;129(2):71–79.

Ray Chaudhuri

Rojo

Schapira

. A proposal for a comprehensive grading of Parkinson’s disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS One. 2013;8(2):e57221.

10.

Zis

Rizos

Martinez Martin

. Non-motor symptoms profile and burden in drug naïve versus long-term Parkinson’s disease patients. J Parkinsons Dis. 2014;4(3):541–547.

11.

Santos-García

de la Fuente-Fernández

. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson’s disease. J Neurol Sci. 2013;332(1-2):136–140.

12.

Santos García

Suárez Castro

Expósito

. Comorbid conditions associated with Parkinson’s disease: a longitudinal and comparative study with Alzheimer disease and control subjects. J Neurol Sci. 2017;373:210–215.

13.

Santos-García

de la Fuente-Fernández

. Factors contributing to caregivers’ stress and burden in Parkinson’s disease. Acta Neurol Scand. 2015;131(4):203–210.

14.

Chaudhuri

Martinez-Martin

Brown

. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord. 2007;22(13):1901–1911.

15.

Fanhn

Elton

; Members of the UPDRS Development Committee. Unified Parkinson’s disease rating scale. In: Fahn

Marsden

Calne

Goldstein

, eds. Recent Developments in Parkinson’s Disease. Vol 2. Florham Park, NJ: Macmillan Health Care Information; 1987:153–164.

16.

Tomlinson

Stowe

Patel

Rick

Gray

Clarke

. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25(15):2649–2653.

17.

Louis

Marder

Cote

Tang

Mayeux

. Mortality from Parkinson disease. Arch Neurol. 1997;54(3):260–264.

18.

Elbaz

Bowe

Petersen

. Survival study of Parkinson disease in Olmsted county, Minnesota. Arch Neurol. 2003;60(1):91–96.

19.

De Lau

Schipper

Hofman

Koudstaal

Breteler

. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neurol. 2005;62(8):1265–1269.

20.

D’Amelio

Ragonese

Morgante

. Long-term survival of Parkinson’s disease: a population-based study. J Neurol. 2006;253:33–37.

21.

Chen

Zhang

Schwarzschild

Hernan

Ascherio

. Survival of Parkinson’s disease patients in a large prospective cohort of male health professionals. Mov Disord. 2006;21(7):1002–1007.

22.

Fink

Kuskowski

Taylor

Schousbot

Orwoll

Ensrud

. Association of Parkinson’s disease with accelerated bone loss, fractures and mortality in older men: the Osteoporotic Fractures in Men (MrOS) study. Osteoporos Int. 2008;19(9):1277–1282.

23.

Driver

Kurth

Buring

Gaziano

Logroscino

. Parkinson disease and risk of mortality: a prospective comorbidity-matched cohort study. Neurology. 2008;70(16 pt 2):1423–1430.

24.

Posada

Benito-León

Louis

. Mortality from Parkinson’s disease: a population-based prospective study (NEDICES). Mov Disord. 2011;26(14):2522–2529.

25.

Fall

Saleh

Fredrickson

Olsson

Granerus

. Survival time, mortality, and cause of death in elderly patients with Parkinson’s disease: a 9-year follow up. Mov Disord. 2003;18(11):1312–1316.

26.

Morgante

Salemi

Meneghini . Parkinson disease survival: a population-based study. Arch Neurol. 2000;57(4):507–512.

27.

Berger

Breteler

Helmer

. Prognosis with Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic diseases in the elderly research group. Neurology. 2000;54(11 suppl 5):S24–S47.

28.

Morens

Davis

Gradinetti

Ross

Popper

White

. Epidemiologic observations on Parkinson’s disease: incidence and mortality in a prospective study of middle-aged men. Neurology. 1996;46(4):1044–1050.

29.

Enmeier

Calder

Crawford

Stewart

Besson

Mutch

. Mortality and causes of death in idiopathic Parkinson’s disease: results from the Aberdeen whole population study. Scott Med J. 1990;35(6):173–175.

30.

Beyer

Herlofson

Arsland

Larsen

. Causes of death in a community-based study of Parkinson’s disease. Acta Neurol Scand. 2001;103(1):7–11.

31.

Hughes

Ross

Mindham

Spokes

. Mortality in Parkinson’s disease and its association with dementia and depression. Acta Neurol Scand. 2004;110(2):118–123.

32.

Duarte

Garcia

Mendoza

Claveria

. The natural history of Parkinson’s disease in the province of Segovia: mortality in a longitudinal study (20-year follow-up). Acta Neurol Scand. 2013;127(5):295–300.

33.

Bennett

Beckett

Murray

. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med. 1996;334(2):71–76.

34.

Akbar

Dham

. Incidence and mortality trends of aspiration pneumonia in Parkinson’s disease in the United States, 1979-2010. Parkinsonism Relat Disord. 2015;21(9):1082–1086.

35.

Martinez-Ramirez

Almeida

Giugni

. Rate of aspiration pneumonia in hospitalized Parkinson’s disease patients: a cross-sectional study. BMC Neurol. 2015;15:104.

36.

Buter

van den Hout

Matthews

Larsen

Brayne

Aarsland

. Dementia and survival in Parkinson disease: a 12-year population study. Neurology. 2008;70(13):1017–1022.

37.

Levy

Tang

Louis

. The association of incident dementia with mortality in PD. Neurology. 2002;59(11):1708–1713.

38.

Reddy

Martinez-Martin

Rizos

. Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effects. Clin Neuropharmacol. 2012;35(5):205–207.

39.

Merola

Espay

Romagnolo

. Advanced therapies in Parkinson’s disease: long-term retrospective study. Parkinsonism Relat Disord. 2016;29:104–108.

40.

Aarsland

Brønnick

Ehrt

. Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated caregiver stress. J Neurol Neurosurg Psychiatry. 2007;78(1):36–42.

41.

Carter

Stewart

Lyons KS Archbold

. Do motor and nonmotor symptoms in PD patients predict caregiver strain and depression? Mov Disord. 2008;23(9):1211–1221.

42.

Schulz

Beach

. Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. JAMA. 1999;282(23):2215–2219.

43.

Martínez-Martín

Chaudhuri

Rojo-Abuin

Assessing the non-motor symptoms of Parkinson’s disease: MDS-UPDRS and NMS Scale. Eur J Neurol. 2015;22:2–3. http://www.movementdisorders.org/MDS/Education/Rating-Scales/MDS-Recommended-Rating-Scales.htm.

44.

Antonini

Bauer

Dohin

. Effects of rotigotine transdermal patch in patients with Parkinson’s disease presenting with non-motor symptoms—results of a double-blind, randomized, placebo-controlled trial. Eur J Neurol. 2015;22(10):1400–1407.